While the COVID-19 pandemic has begun to ease in the United States and governments similarly move from stay-at-home orders to an easing of restrictions, testing remains key to limiting the spread of the virus, and Stratasys is working hard to help testing centers gain access to the nasopharyngeal (NP) swabs they need.
According to the COVID Tracking Project, new tests across the country have been above 300,000 nearly every day since mid-May, with a new high of 545,690 tests reported on Friday, June 5. This is more than twice the rate of testing reported in mid-April. The demand continues to grow.
Since early May, Stratasys has been marketing and promoting Origin 3D-printed nasal swabs to healthcare providers and other testing centers in the U.S. And now, all these NP swabs (NP-01-S) are sterile, individually packaged, and ready to use out of the box.
The Origin 3D-printed NP swab (NP-01-S) has been tested in a clinical trial and is considered an FDA Class I Exempt Device. The trial was conducted by Beth Israel Deaconess Medical Center, an academic medical center affiliated with Harvard Medical School.
